Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average) (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $257.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 21.91% to $257.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $257.2 million, a 21.91% increase, with the full-year FY2025 number at $257.2 million, up 21.91% from a year prior.
  • Shares Outstanding (Weighted Average) was $257.2 million for Q4 2025 at Akebia Therapeutics, up from $254.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $257.2 million in Q4 2025 to a low of $153.8 million in Q1 2021.
  • A 5-year average of $198.0 million and a median of $186.6 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 1.2% in 2023, then rose 22.1% in 2025.
  • Akebia Therapeutics' Shares Outstanding (Weighted Average) stood at $165.9 million in 2021, then grew by 10.14% to $182.8 million in 2022, then grew by 2.56% to $187.5 million in 2023, then grew by 12.53% to $210.9 million in 2024, then grew by 21.91% to $257.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Shares Outstanding (Weighted Average) are $257.2 million (Q4 2025), $254.4 million (Q3 2025), and $249.1 million (Q2 2025).